Cobblestone area-forming cells, long-term culture-initiating cells and NOD/SCID repopulating cells in human neonatal blood: a comparison with umbilical cord blood

Limiting-dilution analysis of long-term culture-initiating cells (LTCIC) is a quantitative method of estimating hematopoietic stem cell activity in clinical samples. We compared the numbers of LTCIC in bone marrow (BM), umbilical cord blood, and blood progenitor cells (obtained from patients with solid tumors at leukapheresis after mobilization with induction chemotherapy and filgrastim administration), using a two- stage long-term culture system and a limiting-dilution technique, scoring cobblestone areas of greater than 15 hematopoietic cells weekly for up to 8 weeks. Samples were obtained from 30 normal BMs, 20 human umbilical cords, and 32 leukapheresis products. Direct comparison of LTCIC in the three sources showed that the median proportions of cells generating hematopoietic foci from unfractionated mononuclear cells at 5 and 8 weeks, respectively, were 1:13,314 and 1:33,949 for BM, 1:12,506 and 1:34,546 for umbilical cord blood, and 1:10,302 and 1:12,891 for leukapheresis product. The estimated proportions of LTCIC from unfractionated mononuclear cells and CD34+ cells were similar in experiments with leukapheresis product. Leukapheresis product was superior to umbilical cord blood and cord blood to BM at 5 and 8 weeks of culture (P = .01). In two-stage long-term cultures, more colonies per flask and CD34+ cells were found in assays of leukapheresis product than in BM or umbilical cord blood cultures (P = .0005). Results obtained by this simplified limiting-dilution analysis correlated well with standard long-term cultures and can be used as a measure of the stem cell population. These data suggest that the incidence of putative stem cells in leukapheresis product and umbilical cord blood are at least comparable with that of BM.

Download Full-text

EXPRESSION OF HLA DR IN LONG TERM CULTURE OF HUMAN UMBILICAL CORD BLOOD(HUCB) B/B CELL DIFFERENTIATE RESPONSE: TO BE LOOK OUT FOR EVENTUAL REJECTION IN HUCB TRANSPLANTATION

Transplantation Journal ◽

10.1097/00007890-201007272-02046 ◽

2010 ◽

Vol 90 ◽

pp. 1040

Author(s):

S. -. Rafiei ◽

J. Santuli ◽

M. Ebrahimi ◽

Taheri R. Panah ◽

N. Mosafa

Keyword(s):

Cord Blood ◽

B Cell ◽

Umbilical Cord ◽

Umbilical Cord Blood ◽

Human Umbilical Cord Blood ◽

Human Umbilical Cord ◽

Long Term Culture ◽

Hla Dr

Download Full-text

Long-term engraftment stability of umbilical cord blood cells preserved in −135 °C mechanical freezers

Leukemia Research ◽

10.1016/j.leukres.2021.106590 ◽

2021 ◽

pp. 106590

Author(s):

Harumi Kato ◽

Hirofumi Taji ◽

Takeshi Kodaira ◽

Tomohiro Kinoshita ◽

Kazuhito Yamamoto

Keyword(s):

Cord Blood ◽

Umbilical Cord ◽

Umbilical Cord Blood ◽

Blood Cells ◽

Cord Blood Cells ◽

Umbilical Cord Blood Cells

Download Full-text

High Integrity and Fidelity of Long-Term Cryopreserved Umbilical Cord Blood for Transplantation

Journal of Clinical Medicine ◽

10.3390/jcm10020293 ◽

2021 ◽

Vol 10 (2) ◽

pp. 293

Author(s):

Gee-Hye Kim ◽

Jihye Kwak ◽

Sung Hee Kim ◽

Hee Jung Kim ◽

Hye Kyung Hong ◽

...

Keyword(s):

Stem Cell ◽

Cord Blood ◽

Umbilical Cord ◽

Umbilical Cord Blood ◽

Clinical Applications ◽

Hematopoietic Stem ◽

Cd34 Cells ◽

Hsc Transplantation

Umbilical cord blood (UCB) is used as a source of donor cells for hematopoietic stem cell (HSC) transplantation. The success of transplantation is dependent on the quality of cord blood (CB) units for maximizing the chance of engraftment. Improved outcomes following transplantation are associated with certain factors of cryopreserved CB units: total volume and total nucleated cell (TNC) count, mononuclear cell (MNC) count, and CD34+ cell count. The role of the storage period of CB units in determining the viability and counts of cells is less clear and is related to the quality of cryopreserved CB units. Herein, we demonstrate the recovery of viable TNCs and CD34+ cells, as well as the MNC viability in 20-year-old cryopreserved CB units in a CB bank (MEDIPOST Co., Ltd., Seongnam-si, Gyeonggi-do, Korea). In addition, cell populations in CB units were evaluated for future clinical applications. The stable recovery rate of the viability of cryopreserved CB that had been stored for up to 20 years suggested the possibility of uses of the long-term cryopreservation of CB units. Similar relationships were observed in the recovery of TNCs and CD34+ cells in units of cryopreserved and fresh CB. The high-viability recovery of long-term cryopreserved CB suggests that successful hematopoietic stem cell (HSC) transplantation and other clinical applications, which are suitable for treating incurable diseases, may be performed regardless of long-term storage.

Download Full-text

Alternative Donor Transplantation for Aplastic Anemia

Hematology ◽

10.1182/asheducation-2010.1.43 ◽

2010 ◽

Vol 2010 (1) ◽

pp. 43-46 ◽

Cited By ~ 16

Author(s):

Mary Eapen ◽

Mary M. Horowitz

Keyword(s):

Cord Blood ◽

Aplastic Anemia ◽

Umbilical Cord ◽

Umbilical Cord Blood ◽

Graft Failure ◽

Hla Typing ◽

Unrelated Donor ◽

Term Survival ◽

Alternative Donor

AbstractPatients with severe aplastic anemia who do not have a human leukocyte antigen (HLA)-identical sibling generally receive immunosuppressive therapy as a first-line therapy, with allogeneic transplantation being reserved for those who do not have an adequate sustained response. Barriers to the use of unrelated-donor transplantation for aplastic anemia include identifying a suitable alternative donor, and risks of graft failure, regimen-related toxicity, and graft-versus-host disease (GVHD). Despite the more than 14 million adults registered with donor registries worldwide, only approximately 50% of patients of Caucasian descent will have an available and fully HLA-matched unrelated adult donor; the rate is substantially lower for non-Caucasians. While umbilical cord blood allows transplantation with greater donor-recipient HLA disparity (without excessive risk of GVHD), risks of graft failure and transplant-related mortality are higher than after transplantation of adult donor grafts. Among patients with a suitable donor, recent changes in pre-transplant conditioning regimens have lowered the risks of organ toxicity and graft failure. Although advances in donor HLA typing and selection practices and improved GVHD prophylaxis have lowered the risk, GVHD remains an important obstacle to long-term symptom-free survival. Despite these limitations, unrelated-donor transplantation offers the best chance of long-term survival for many patients in whom current immunosuppression strategies are not effective. Wider applicability of alternative-donor transplantation for aplastic anemia will require better approaches to prevent graft failure and GVHD and to expand the pool of unrelated-donor grafts. This includes exploring strategies to effectively use alternative grafts such as umbilical cord blood.

Download Full-text